Your session is about to expire
← Back to Search
SUSTOL Safety for Chemotherapy-Induced Nausea and Vomiting
Study Summary
This trial will test if a person's activities of daily living are impacted by injection-site reactions from SUSTOL®, an injection used to prevent chemotherapy-induced nausea and vomiting.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2007 Phase 4 trial • 171 Patients • NCT00231478Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am scheduled for at least 4 cycles of specific chemotherapy and will use SUSTOL for nausea prevention.I am fully active or restricted in physically strenuous activity but can do light work.My kidneys are not working well (very low filtration rate).I am not pregnant, breastfeeding, or planning to become pregnant during the study.I can take standard doses of medication to prevent vomiting.I am scheduled for chemotherapy and will use SUSTOL for nausea prevention.I can take dexamethasone to prevent vomiting.I am not pregnant, breastfeeding, or planning to become pregnant during the study.I have symptoms from a brain tumor or its spread.I am fully active or restricted in physically strenuous activity but can do light work.You are expected to live for at least six more months.
- Group 1: Treatment Group
- Drug Has Already Been Approved - The FDA has already approved this drug, and is just seeking more data.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is SUSTOL considered to be hazardous for individuals?
"Through an internal evaluation, SUSTOL was deemed to have a safety rating of 3 due its Phase 4 classification, which denotes the regulatory approval of this medication."
What is the sample size of this experiment?
"Correct. Clinicaltrials.gov provides evidence that this research project, initially posted on July 6th 2022 and recently amended on the 15th of July, is actively looking for 300 participants at a single medical centre."
Is this clinical study actively seeking participants?
"Affirmative. According to the information published on clinicaltrials.gov, this medical research is actively recruiting suitable applicants since it was originally posted in June of 2022 and last updated mid-July. The study requires 300 participants who will be assessed at a singular site."
Share this study with friends
Copy Link
Messenger